Cutaneous Malignant Neoplasms in Hematopoietic Cell Transplant Recipients

DePry, Jennifer L.; Vyas, Ritva; Lazarus, Hillard M.; Caimi, Paolo; Gerstenblith, Meg R.; Bordeaux, Jeremy S.

doi:10.1001/jamadermatol.2015.121

Cited by 50 publications

(55 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10,21 This finding was recently confirmed in a systematic review on cutaneous malignant neoplasms in HSCT recipients. 24 For patients undergoing allogeneic HSCT, TBI is often part of the conditioning regimen (67% in our study), whereas RTRs are not exposed to TBI. Furthermore, TBI is not part of the conditioning regimen for autologous HSCT in Denmark.…”

Section: Discussionmentioning

confidence: 82%

Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant Recipients

et al. 2016

View full text Add to dashboard Cite

IMPORTANCE While a high risk of nonmelanoma skin cancer is well recognized in solid-organ transplant recipients, the risk of skin cancer in hematopoietic stem-cell transplant (HSCT) recipients has not been extensively studied.OBJECTIVE To determine the risk of cutaneous cancer in HSCT recipients and compare it with the risk in renal transplant recipients (RTRs) and individuals who have not received any transplant.

show abstract

Section: Discussionmentioning

confidence: 82%

Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant Recipients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The link between skin cancer development and immunosuppression is well established and thus the finding that 35% ( n =36) of cases were NMSCs is not surprising. 21 The 3-year cumulative incidence of SPM falls to 2.9% when NMSCs are excluded.…”

Section: Discussionmentioning

confidence: 99%

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

Jones

Cairns

Gregory

et al. 2016

Blood Cancer Journal

View full text Add to dashboard Cite

We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary malignancy (SPM) incidence and pathology. After review, 104 SPMs were confirmed in 96 of 2732 trial patients. The cumulative incidence of SPM was 0.7% (95% confidence interval (CI) 0.4–1.0%), 2.3% (95% CI 1.6–2.7%) and 3.8% (95% CI 2.9–4.6%) at 1, 2 and 3 years, respectively. Patients receiving maintenance lenalidomide had a significantly higher SPM incidence overall (P=0.011). Age is a risk factor with the highest SPM incidence observed in transplant non-eligible patients aged >74 years receiving lenalidomide maintenance. The 3-year cumulative incidence in this group was 17.3% (95% CI 8.2–26.4%), compared with 6.5% (95% CI 0.2–12.9%) in observation only patients (P=0.049). There was a low overall incidence of haematological SPM (0.5%). The higher SPM incidence in patients receiving lenalidomide maintenance therapy, especially in advanced age, warrants ongoing monitoring although the benefit on survival is likely to outweigh risk.

show abstract

“…Although the majority of these patients survive, they suffer from multiple occurrences, disfigurement and increased expense for health care (31). In a systemic review of 18 studies, the reported median interval to diagnosis after hematopoietic cell transplantation ranged from 7.3 to 9.4 years for BCC and the 20-year cumulative incidence was 6.5% (32). Many of these patients received preconditioning total-body irradiation (TBI) as a preparation for hematopoietic cell transplantation (33).…”

Section: Introductionmentioning

confidence: 99%

Ionizing Radiation Exposure and Basal Cell Carcinoma Pathogenesis

Athar

2016

Radiation Research

View full text Add to dashboard Cite

This commentary summarizes studies showing risk of basal cell carcinoma (BCC) development in relationship to environmental, occupational and therapeutic exposure to ionizing radiation (IR). BCC, the most common type of human cancer, is driven by the aberrant activation of hedgehog (Hh) signaling. Ptch, a tumor suppressor gene of Hh signaling pathway, and Smoothened play a key role in the development of radiation-induced BCCs in animal models. Epidemiological studies provide evidence that humans exposed to radiation as observed among the long-term, large scale cohorts of atomic bomb survivors, bone marrow transplant recipients, patients with tinea capitis and radiologic workers enhances risk of BCCs. Overall, this risk is higher in Caucasians than other races. People who were exposed early in life develop more BCCs. The enhanced IR correlation with BCC and not other common cutaneous malignancies is intriguing. The mechanism underlying these observations remains undefined. Understanding interactions between radiation-induced signaling pathways and those which drive BCC development may be important in unraveling the mechanism associated with this enhanced risk. Recent studies showed that Vismodegib, a Smoothened inhibitor, is effective in treating radiation-induced BCCs in humans, suggesting that common strategies are required for the intervention of BCCs development irrespective of their etiology.

show abstract

Cutaneous Malignant Neoplasms in Hematopoietic Cell Transplant Recipients

Abstract: Given the increased risk of cutaneous malignant neoplasms in hematopoietic cell transplant recipients, this population should be educated on skin self-examination and pursue regular follow-up with dermatologists.

Cited by 50 publications

References 38 publications

Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant Recipients

Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant Recipients

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

Ionizing Radiation Exposure and Basal Cell Carcinoma Pathogenesis

Contact Info

Product

Resources

About